Low-Frequency Sensorineural Hearing Loss in Familial Hemophagocytic Lymphohistiocytosis Type 5

2018 ◽  
Vol 127 (6) ◽  
pp. 409-413 ◽  
Author(s):  
Aren Bezdjian ◽  
Hanneke Bruijnzeel ◽  
Julia Pagel ◽  
Sam J. Daniel ◽  
Hans G.X.M. Thomeer

Introduction: Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive disease affecting the cytotoxic pathway. Due to the recent advances in molecular diagnosis, immuno-chemo therapy, and hematopoietic stem cell transplantation treatment, FHL survival rates have drastically increased. Case Presentation: Herein, we describe a case of FHL type 5 presenting with low-frequency sensorineural hearing loss. Alongside our reported case, 6 additional patients were identified in the literature. Management and Outcome: The progressive nature of FHL disorder may cause bilateral, low-frequency, irreversible sensorineural hearing loss. This type of hearing loss should be considered among the long-term sequelea presenting with FHL5. Discussion: We recommend audiological evaluation at initial FHL5 diagnosis to assess for hearing functions. Follow-up in audiology should be part of the long-term monitoring of patients with FHL5 as hearing loss could develop long after diagnosis.

2017 ◽  
Vol 2 (5) ◽  
pp. 262-268 ◽  
Author(s):  
Taha A. Jan ◽  
Aaron K. Remenschneider ◽  
Christopher Halpin ◽  
Margaret Seton ◽  
Michael J. McKenna ◽  
...  

2016 ◽  
Vol 21 (3) ◽  
pp. 132-140 ◽  
Author(s):  
Shinya Morita ◽  
Yuji Nakamaru ◽  
Keishi Fujiwara ◽  
Keiji Iizuka ◽  
Masayori Masuya ◽  
...  

Objectives: To evaluate the hearing outcomes of intratympanic steroid (ITS) treatment for patients with acute low-tone sensorineural hearing loss (ALHL) after failure of initial therapy and to investigate the recurrence and progression to definite Ménière's disease (MD) during a long-term follow-up. Methods: We retrospectively reviewed the medical records of 90 patients with refractory ALHL who were followed up for at least 1 year between January 2000 and April 2014. Patients who responded poorly to initial medical treatment received intratympanic dexamethasone injections (ITS group) or isosorbide administration for 4 weeks (diuretic group) as salvage treatment options according to their choice of management. The control group did not receive ITS or the diuretic, due to their refusal of both medical treatments. The hearing outcomes were evaluated 1 month, 1 year and 5 years after the completion of the second-line therapy, and the rates of recurrence and progression to MD were measured during a follow-up period of at least 1 year. Results: Twenty-seven patients in the ITS group, 39 patients in the diuretic group and 24 patients in the control group were enrolled. Of these, 12 patients in the ITS group, 15 patients in the diuretic group and 12 patients in the control group were followed up for over 5 years. We found that the recovery rates and the audiometric functional values after 1 month and 1 year in the ITS group were significantly higher than those in the diuretic and control groups. However, there were no significant differences in the recovery rates or the audiometric functional values after 5 years, or in the rates of recurrence and progression to MD between the groups. Conclusions: Salvage ITS therapy can provide a relatively good short-term hearing outcome for ALHL patients who have persistent hearing loss despite conventional treatment. However, both recurrence and progression to MD after treatment were observed in some patients during the long-term follow-up.


2007 ◽  
Vol 49 (6) ◽  
pp. 856-858 ◽  
Author(s):  
Shinsaku Imashuku ◽  
Urara Kohdera ◽  
Tomoko Teramura ◽  
Ikuyo Ueda ◽  
Akira Morimoto ◽  
...  

1994 ◽  
Vol 37 (4) ◽  
pp. 310-315
Author(s):  
Eiji Chida ◽  
Nobukiyo Satoh ◽  
Mitsugu Kawanami ◽  
Masaaki Kashiwamura ◽  
Satoshi Fukuda ◽  
...  

2014 ◽  
Vol 128 (8) ◽  
pp. 669-673 ◽  
Author(s):  
I Dallan ◽  
S Fortunato ◽  
A P Casani ◽  
E Bernardini ◽  
S Sellari-Franceschini ◽  
...  

AbstractObjective:To evaluate the long-term stability of intratympanic steroids and investigate the ‘real’ impact of sudden sensorineural hearing loss on patients.Method:A total of 14 patients treated with intratympanic steroids were evaluated by audiometric and vestibular examinations. The modified Glasgow Benefit Inventory was used to evaluate quality of life changes after intratympanic steroid treatment.Results:There was no significant difference between pure tone average post-intratympanic steroids and at follow up. The general Glasgow Benefit Inventory score was not significantly associated with the presence of tinnitus or dizziness, or with patient age. The change in pure tone average after intratympanic steroid treatment did not correlate with social or physical scores, but correlated strongly with the general Glasgow Benefit Inventory score (p = 0.0023). Intratympanic steroid administration led to a stable improvement in hearing. Quality of life assessment showed that patients can feel satisfaction regardless of the hearing outcome. Patients who regained a social hearing level expressed greater satisfaction than patients without serviceable hearing. Overall, quality of life improvement was not related to hearing improvement.Conclusion:Sudden sensorineural hearing loss is devastating. Considering the audiological effects alone ignores the ‘human’ perspective. Audiological success can correlate with poor quality of life outcome.


1994 ◽  
Vol 37 (2) ◽  
pp. 142-149 ◽  
Author(s):  
Masatoshi Hirayama ◽  
Tetsuya Shitara ◽  
Makito Okamoto ◽  
Hajime Sano

Sign in / Sign up

Export Citation Format

Share Document